drugset / Trial / NCT05753059
Mechanisms of Diuretic Resistance in Heart Failure, Aim 2
Phase 1
Recruiting
50 enrolled
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedCrossoverTriple-blindOther
Summary
Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.
Timeline
- Start
- 2023-08-10
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amiloride | Small molecule | — | — |
| Comparator | Bendroflumethiazide | Small molecule | — | — |